Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.80 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.80 |
| ▸ | CLK1 | P49759 | 5/20 | 0.80 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.80 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.80 |
| ▸ | KIT | P10721 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | USP7 | Q93009 | 1/20 | 0.66 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.63 |
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.62 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.62 |
| ▸ | SGK1 | O00141 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319204 | 0.91 | NTRK1 (0.80) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL4167572 | 0.90 | NTRK1 (0.79) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3766005 | 0.89 | NTRK1 (0.77) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL12763363 | 0.89 | DYRK1A (0.80) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3760839 | 0.89 | NTRK1 (1.00) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL4164044 | 0.89 | NTRK1 (0.76) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3775679 | 0.89 | NTRK1 (0.76) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3768119 | 0.88 | RIPK1 (0.81) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3761694 | 0.87 | NTRK1 (0.84) | NTRK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL4160145 | 0.87 | NTRK1 (0.77) | NTRK1DYRK1ACLK1DYRK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| EP-3545956-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3545956-A1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | Arrien Pharmaceuticals LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-2986300-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2014172513-A2 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | JAK3, ITK, JAK2 | NTRK1 2318/4885DYRK1A 738/4885CLK1 106/4885 |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | JAK3, TYK2, JAK2 | NTRK1 1914/4885DYRK1A 344/4885CLK1 36/4885 |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | NTRK1 964/4885DYRK1A 378/4885CLK1 254/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | NTRK1 997/4885DYRK1A 360/4885CLK1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.